Evox Therapeutics awarded key exosome patents in the US and Europe.
M2 EQUITYBITES-August 7, 2019-Evox Therapeutics awarded key exosome patents in the US and Europe
(C)2019 M2 COMMUNICATIONS http://www.m2.com
Biotechnology company Evox Therapeutics Ltd Wednesday received three key patents from the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) covering its exosome therapeutics pipeline in the US and Europe.
These three new grants are from one of several foundational patent families held by the company and further reinforce its leading position within exosome-mediated RNA therapeutics and targeted exosome drug delivery.
The company's two new US patents, which has been assigned the numbers 10,329,561 and 10,233,445, provide coverage for pharmaceutical compositions comprising exosomes containing exogenous genetic material, such as RNAi agents and antisense oligonucleotides, and targeting of exosomes to tissues of interest, respectively.
In conjunction, the company's newly granted European patent, which has been assigned the No 2419144, provides coverage for loading of exogenous genetic material into exosomes as well as targeted exosome-mediated delivery to tissues and organs of interest.
((Comments on this story may be sent to email@example.com))